How Wegovy works in the body: the GLP-1 mechanism explained

What GLP-1 does, and why Wegovy amplifies it

GLP-1 stands for glucagon-like peptide-1. Your intestine releases it in the minutes after you eat, and it does several things at once: it signals satiety to the brain, tells the pancreas to release insulin in response to glucose, and slows the rate at which the stomach empties into the small intestine. Under normal circumstances, GLP-1 is broken down within a few minutes by an enzyme called DPP-4, so the effect is brief.

Semaglutide (the molecule in Wegovy) is a synthetic analogue of GLP-1, structurally modified so the same enzyme can't destroy it quickly. A single weekly injection produces sustained receptor activation that your own post-meal GLP-1 pulse never achieves. That extended signal is why the effect on appetite is ongoing rather than peaking and fading with each meal.

The NHS medicines page for semaglutide describes this mechanism plainly: it works by increasing feelings of fullness and reducing hunger. Both things happen, and they happen through distinct but complementary pathways.

Three places in the body where semaglutide has a measurable effect

The brain is the most discussed site. GLP-1 receptors are clustered in the hypothalamus and brainstem, regions that process hunger and reward signals. Semaglutide binding there appears to reduce the drive to eat beyond caloric need, which many people experience as simply not thinking about food as much rather than using willpower to resist it. If you'd like a fuller picture of how Wegovy works in the body, we've covered the biological detail in a dedicated guide.

The stomach is the second site. Gastric emptying slows, so a modest amount of food produces a fullness sensation that arrives earlier and lingers longer. For some people this is the most noticeable effect in the first weeks of treatment.

The pancreas is the third. Semaglutide stimulates insulin secretion in a glucose-dependent way, meaning it responds to rising blood sugar rather than firing constantly. This is why the medicine is also used in type 2 diabetes management, though the licensed weight-management indication (as Wegovy) is separate from diabetes products like Ozempic, which contains the same active ingredient but in a different-strength formulation approved for a different purpose. For a more detailed look at how Wegovy works across all three of these sites, our dedicated page walks through each pathway in turn.

If you're weighing up how semaglutide compares with other mechanisms, our semaglutide overview covers the broader landscape.

What the evidence says about weight outcomes in practice

The STEP 1 trial is the anchor study. It randomised 1,961 adults with obesity or overweight plus a weight-related condition, without diabetes, to either semaglutide 2.4mg weekly or placebo, both alongside lifestyle counselling, for 68 weeks. The semaglutide group lost an average of around 15% of body weight; the placebo group around 2.4%. That gap is large enough to be clinically meaningful across a population.

NICE reviewed this evidence and recommended semaglutide (Wegovy) for use within specialist weight management services, under specific eligibility criteria and for a maximum of two years, alongside multidisciplinary support. The NICE guidance is explicit that treatment should be considered for stopping if less than 5% weight loss is achieved after six months on the maintenance dose.

For a private route, the eligibility picture is somewhat different, the licensed criteria centre on BMI and weight-related conditions, assessed individually by a prescriber. You can read more about Wegovy on the nume site, or if you're curious about how costs compare across treatment options, our Wegovy prices page covers what a legitimate private prescription typically includes. Current treatment pricing and options are on the weight-loss treatments page.

Side effects: what the mechanism predicts, and what the trials found

Because GLP-1 receptors line the gut as well as the brain, the most common side effects follow the digestive system: nausea, vomiting, diarrhoea, constipation, indigestion and burping appear most often in the early weeks of treatment or after a dose increase, then typically settle as the body adjusts. Knowing this in advance is practically useful, if you notice nausea peaking around the first day or two after each injection, that timing reflects the peak in drug concentration. Keeping that pattern in mind, and checking whether symptoms ease by mid-week, is a quick self-check that takes under a minute and helps distinguish normal adjustment from something worth flagging to your prescriber. Our guide on how Wegovy works in your body explains why these early digestive symptoms follow a predictable pattern and what to expect as your system adjusts.

On the rarer but serious end: the MHRA highlighted acute pancreatitis in a Drug Safety Update for GLP-1 medicines in January 2026. The symptom to act on urgently is severe, persistent abdominal pain that radiates to the back, with or without vomiting. This is uncommon, but it warrants immediate medical attention rather than a wait-and-see approach. Side effects (expected or unexpected) can be reported through the MHRA's Yellow Card scheme.

Wegovy is not recommended during pregnancy, breastfeeding, or when trying to conceive. It is not licensed for anyone under 18. These are absolute restrictions, not caveats, a prescriber won't adjust them based on circumstances.

Our clinical team, led by our Independent Prescriber, reviews every consultation personally. If the evidence points to Wegovy being suitable for you, treatment can be dispatched the same working day.